Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
2024年 4月 15日
Read MoreZai Lab Statement on Executive Management Team’s Agreement on Share Activities
2024年 4月 11日
Read MoreZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
2024年 4月 02日
Read MoreZai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2024年 4月 01日
Read MoreZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
2024年 3月 27日
Read MoreZai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
2024年 3月 13日
Read MoreZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
2024年 3月 06日
Read More